tirzepatide children Efficacy and safety of in and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial LLY -0.60% today as Lilly's

Hair and follicle support Evidence sources : mixed, with fewer human trials Confidence : low Main caveats : endpoints can differ, such as density, thickness, or shedding, which makes comparisons difficult

doi: 10.3389/fmed.2025.1713327 Received 25 September 2025 Revised 01 December 2025 Accepted 08 December 2025 Published 02 January 2026 Volume 12 - 2025 Edited by Jianjing Lin, Peking University, China Reviewed by Wei Wei, Harbin Medical University, China Jian Zhang, Guizhou University of Traditional Chinese Medicine, China Updates Copyright 2026 Zhu, Wu, Peng, He, Hu and Xiao

Tirzepatide delivers proven, FDA-approved results with years of safety data behind it

Your healthcare provider will closely examine your individual situation, insurance coverage, and preferences to determine the most suitable option, ensuring seamless integration into your lifestyle